ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
Conditions
Keywords
ALS, tocilizumab, biomarker
Brief summary
This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS). The investigators also want to find out if tocilizumab is safe to take without causing too many side effects. Currently ALS has no cure and 2 modestly effective treatment to slow the progression of the disease. Although not the initial cause of ALS, the immune system plays a role in the death of motor neurons. The immune cells that participate in this process are stimulated by a substance called interleukin-6 (IL-6) whose effect is blocked by tocilizumab and thus, may slow the death of motor neurons and slow the disease.
Detailed description
This is a multicenter, randomized, double-blind, placebo-controlled 16-week study evaluating the safety and tolerability of tocilizumab in subjects with ALS. The primary objective of the study is to determine the safety and tolerability of intravenous administration of 8 mg/kg of tocilizumab every 4 weeks vs. matched intravenous placebo administered every 4 weeks over an 8 week period. The secondary objectives of the study are to describe the expression of pro-inflammatory genes in Peripheral Blood Mononuclear Cells (PBMCs) of sporadic ALS patients, to assess the ability of tocilizumab to reduce the expression of pro-inflammatory genes in PBMCs and pro-inflammatory cytokines in the cerebrospinal fluid (CSF) of patients with sporadic ALS and to assess the CSF penetration of tocilizumab. Mean peripheral benzodiazepine receptor 28 (PBR28) uptake will be measured in the motor cortices as regions of interest (ROIs), and will be compared between pre- and post-dose, for Massachusetts General Hospital (MGH) subjects. Approximately 5 Northeast ALS Consortium (NEALS) Centers in the US will participate in the study. Twenty-four subjects will be randomized in the study. This study will be conducted in subjects who meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS. At screening, eligible subjects must be at least 18 years old, must have a slow vital capacity (SVC) ≥ 40% of predicted capacity for age, height and gender (and in the opinion of the investigator is able to comply with and complete the trial), and must provide written informed consent prior to screening. Subjects on a stable dose of riluzole and those not taking riluzole, and women of child-bearing age at screening are eligible for inclusion as long as they meet specific protocol requirements. Detailed criteria are described in the body of the protocol. Subjects participating in the magnetic resonance imaging - positron emission tomography (MRI-PET) portion of the study (MGH only) must meet the following additional criteria.High or mixed affinity to bind translocator protein (TSPO) (Ala/Ala or Ala/Thr,) Upper Motor Neuron Burden (UMNB) Scale Score ≥25 (out of 45) at the Screening Visit. and have the ability to safely undergo MRI-PET scans based on the opinion of the site investigator. Subjects will be randomly assigned in a 2:1 ratio to intravenous tocilizumab 8 mg/kg or matching placebo every 4 weeks over an 8 week period. This research study protocol allows the subject to receive up to 3 infusions of Tocilizumab. Even if the treatment is shown to be of benefit, additional infusions of Tocilizumab beyond that allowed in the protocol cannot be given to the subject while she/he is participating in this study. Subjects will remain on randomized, placebo-controlled, double-blind treatment until the Week 8 visit. Each randomized subject will also have a Week 12 Follow-up visit and Week 16 End-of-Study visit to assess for adverse events (AEs), changes in concomitant medications, to administer the ALS Functional Rating Scale (ALSFRS-R) and selected study procedures.
Interventions
DRUGTocilizumab
IV Infusion
OTHERPlacebo
IV Infusion
Sponsors
ALS Association
Barrow Neurological Foundation
Massachusetts General Hospital
Genentech, Inc.
Barrow Neurological Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Participants with ALS (El Escorial criteria: possible, laboratory-supported probable, probable or definite) * Capable of providing informed consent and complying with trial procedures. * High inflammatory profile of PBMC gene expression * Upright SVC ≥40% of predicted value for gender, height and age at Screening and in the opinion of the investigator is able to comply with and complete the trial. * Women must not be able to become pregnant for the duration of the study. * Negative tuberculosis blood or skin test at Screening * Not taking riluzole, or on a stable dosage for at least 30 days prior to Screening. * Subjects medically able to undergo lumbar puncture (LP) * Subjects must agree not to take live attenuated vaccines 30 days before Screening, throughout the duration of the trial and for 60 days following the subject's last dose of study drug * Geographic accessibility to the study site Additional MRI-PET Inclusion Criteria (MGH only): * High or mixed affinity to bind TSPO protein (Ala/Ala or Ala/Thr) (see section 7.1) * Upper Motor Neuron Burden (UMNB) Scale Score ≥25 (out of 45) at the Screening Visit. * Able to safely undergo MRI-PET scans based on the opinion of the site investigator.
Exclusion criteria
* Prior use of Tocilizumab, cell-depleting therapies, alkylating agents, total lymphoid irradiation * Stem cell therapies * Dependence on mechanical ventilation as defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use * Presence of tracheostomy at Screening * Exposure to any anti-inflammatory agent currently under investigation for the treatment of patients with ALS (off label use or investigational) within 30 days prior to the Screening Visit (examples include NP001 and Lunasin). Medications that do not have an anti-inflammatory mechanism, such as mexiletine or retigabine are allowed if on stable dose for 30 days prior to Screening visit * Treatment with a prohibited medication within 30 days of the Screening Visit * Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of Screening * Presence of diaphragm pacing system at Screening. * Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation * History of or active diverticulitis, diverticulosis requiring antibiotic treatment, peptic ulcer disease, or gastrointestinal (GI) tract perforation, or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations * Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections. * History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies * Presence of any of the following clinical conditions: bleeding diathesis, or any other clinical condition that would, in the opinion of the investigator, place the patient at increased risk during LP. Drug abuse or alcoholism within the past 12 months. Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active infectious disease, including current or prior malignancy. Rheumatic autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis. Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years. Human immunodeficiency virus infection or other immunodeficient state.Uncontrolled hypertension defined as systolic blood pressure \> 170 or diastolic blood pressure \> 110. Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the Screening Visit * Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening * Screening alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin \> than 1.5 times the upper limit of normal (ULN), serum creatinine \> 1.6 mg/dL in female patients and \> 1.9 mg/dL in male patients (patients with serum creatinine values exceeding limits may be eligible for the study if their estimated glomerular filtration rate (GFR) are \>30), hemoglobin \< 85 g/L, white blood cells \< 3.0 x 109/L, absolute neutrophil count of \<2000/mm3, absolute lymphocyte count \< 0.5 x 109/L, platelet concentration of \<100,000/mm3, positive Hepatitis B surface antigen (HBsAg) * Pregnant women or women currently breastfeeding * No history of chicken pox infection or no history of varicella zoster vaccination * Any reason in the opinion of the investigator that the patient may not be able to comply with study procedures, complete the study or is unsuitable for immunosuppressive therapy. Additional MR-PET
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Tolerant to Study Drug | 16 weeks | Tolerability will be assessed by on the proportion of participants remaining on study drug through all 3 doses and remaining on study and free from possibly drug-related and dose-limiting SAEs to the end of follow-up. Safety will be assessed by the occurrence of severe adverse events (SAEs), overall rates of adverse events (AEs), clinically significant abnormal laboratory tests, and changes in vital signs. |
| Rates of All-cause Mortality | 16 weeks | Safety will be assessed by the occurrence of all-cause mortality. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Decline Handheld Dynamometry (HHD) | 16 weeks | Efficacy will be assessed by the change in the rate of change of HHD upper and lower extremity mega-scores. HHD utilizes an electronic pressure sensor to measure strength of individual muscles in kilograms. To calculate megascores, the mean and standard deviation of each muscle or muscle group, without regard to laterality, will be calculated from the baseline assessment of all participants. Strength estimates of each bilateral muscle or muscle group will be converted to Z scores by subtracting the relevant mean and dividing by the relevant standard deviation. Z scores for all upper extremity measurements (shoulder flexion, elbow flexion, elbow extension, wrist extension, and first dorsal interosseous contraction) and all lower extremity measurements (hip flexion, knee flexion, knee extension, and ankle dorsiflexion) will be averaged to yield upper and lower extremity megascores. Larger values indicate greater strength. |
| Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression | 16 weeks | Target engagement will be assessed by comparing the PBMC fold change in cytokine gene expression from baseline to week 4-16 average of ALS patients receiving drug versus placebo. |
| Changes in Cytokine Levels in the Plasma | 16 weeks | Target engagement will be assessed by mean change in plasma cytokine concentration between weeks 4 and 16 in ALS subjects receiving placebo or active drug. |
| Rate of Decline in Slow Vital Capacity (SVC) | 16 weeks | Efficacy will be assessed by the change in the rate of change of SVC as measured by change in percent predicted per month. The SVC is a measure of lung capacity that is reported as the percent of the predicted value expected based on gender and height. In ALS patients, this measure declines over time as a result of progressive respiratory muscle weakness. |
| Change in CSF Soluble Interleukin-6 (sIL-6) Receptor Concentrations | 8 weeks | Target engagement will be assessed by comparing the mean change in CSF sIL-6 receptor concentrations (ng/mL) between baseline and week 8 of the placebo and active drug groups. |
| Peripheral Benzodiazepine Receptor 28 (PBR28) Positron Emission Tomography (PET) | 8 weeks | Measure the effects of tocilizumab on reducing glial activation measured by PBR28 PET in a subset of trial participants. |
| Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | 8 weeks | Target engagement will be assessed by the mean change in CSF cytokine concentration between baseline and week 8 in ALS subjects receiving placebo or active drug. |
| Rate of Decline ALS Functional Rating Scale Revised (ALSFRS-R) | 16 weeks | Efficacy will be assessed by the mean change in ALSFRS-R total score.The ALSFRS-R scale measures the functional capabilities of an ALS patient in multiple domains such as swallowing, speech, fine motor, and breathing functions. It ranges from a maximum score of 48 for normal functioning to 0 for death or dependance on mechanical ventilation and declines by approximately 1 point per month on average for an ALS patient. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo 8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion | 8 |
| Active Drug 16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion | 14 |
| Total | 22 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 2 | 0 |
Baseline characteristics
| Characteristic | Placebo | Total | Active Drug |
|---|---|---|---|
| Age, Continuous | 59.2 Years STANDARD_DEVIATION 8.6 | 60.9 Years STANDARD_DEVIATION 8.6 | 61.9 Years STANDARD_DEVIATION 8.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 21 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 7 Participants | 21 Participants | 14 Participants |
| Region of Enrollment United States | 8 Participants | 22 Participants | 14 Participants |
| Sex: Female, Male Female | 3 Participants | 6 Participants | 3 Participants |
| Sex: Female, Male Male | 5 Participants | 16 Participants | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 14 |
| other Total, other adverse events | 6 / 8 | 11 / 14 |
| serious Total, serious adverse events | 1 / 8 | 0 / 14 |
Outcome results
Primary
Number of Patients Tolerant to Study Drug
Tolerability will be assessed by on the proportion of participants remaining on study drug through all 3 doses and remaining on study and free from possibly drug-related and dose-limiting SAEs to the end of follow-up. Safety will be assessed by the occurrence of severe adverse events (SAEs), overall rates of adverse events (AEs), clinically significant abnormal laboratory tests, and changes in vital signs.
Time frame: 16 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo Tolerability | Number of Patients Tolerant to Study Drug | 6 Participants |
| Active Drug Tolerability | Number of Patients Tolerant to Study Drug | 12 Participants |
p-value: 0.60295% CI: [0.556, 1.377]Fisher Exact
Primary
Rates of All-cause Mortality
Safety will be assessed by the occurrence of all-cause mortality.
Time frame: 16 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo Tolerability | Rates of All-cause Mortality | Died | 0 Participants |
| Placebo Tolerability | Rates of All-cause Mortality | Alive | 8 Participants |
| Active Drug Tolerability | Rates of All-cause Mortality | Died | 0 Participants |
| Active Drug Tolerability | Rates of All-cause Mortality | Alive | 14 Participants |
Secondary
Change in CSF Soluble Interleukin-6 (sIL-6) Receptor Concentrations
Target engagement will be assessed by comparing the mean change in CSF sIL-6 receptor concentrations (ng/mL) between baseline and week 8 of the placebo and active drug groups.
Time frame: 8 weeks
Population: Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo Tolerability | Change in CSF Soluble Interleukin-6 (sIL-6) Receptor Concentrations | 1.029 ng/mL |
| Active Drug Tolerability | Change in CSF Soluble Interleukin-6 (sIL-6) Receptor Concentrations | 1.836 ng/mL |
p-value: <0.00195% CI: [1.502, 2.121]Mixed Models Analysis
Secondary
Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF)
Target engagement will be assessed by the mean change in CSF cytokine concentration between baseline and week 8 in ALS subjects receiving placebo or active drug.
Time frame: 8 weeks
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Placebo Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | IL-1beta (pg/mL) | 1.498 Fold change in concentration |
| Placebo Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | IL-8 (pg/mL) | 0.946 Fold change in concentration |
| Placebo Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | IL-6 (pg/mL) | 1.242 Fold change in concentration |
| Placebo Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | TNF-alpha (pg/mL) | 0.989 Fold change in concentration |
| Placebo Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | CRP (ng/mL) | 0.641 Fold change in concentration |
| Active Drug Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | TNF-alpha (pg/mL) | 1.066 Fold change in concentration |
| Active Drug Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | CRP (ng/mL) | 0.107 Fold change in concentration |
| Active Drug Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | IL-1beta (pg/mL) | 1.110 Fold change in concentration |
| Active Drug Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | IL-6 (pg/mL) | 4.115 Fold change in concentration |
| Active Drug Tolerability | Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF) | IL-8 (pg/mL) | 1.020 Fold change in concentration |
p-value: 0.01195% CI: [0.043, 0.643]Mixed Models Analysis
p-value: 0.60495% CI: [0.228, 2.405]Mixed Models Analysis
p-value: <0.00195% CI: [1.823, 4.74]Mixed Models Analysis
p-value: 0.58795% CI: [0.813, 1.431]Mixed Models Analysis
p-value: 0.69795% CI: [0.728, 1.595]Mixed Models Analysis
Secondary
Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression
Target engagement will be assessed by comparing the PBMC fold change in cytokine gene expression from baseline to week 4-16 average of ALS patients receiving drug versus placebo.
Time frame: 16 weeks
Population: Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo Tolerability | Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression | PBMC IL-6 fold-change | 1.21 Fold change in gene expression |
| Placebo Tolerability | Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression | PBMC IL-8 fold-change | 1.33 Fold change in gene expression |
| Placebo Tolerability | Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression | PBMC Matrix Metalloproteinase 1 (MMP1)fold-change | 1.01 Fold change in gene expression |
| Active Drug Tolerability | Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression | PBMC IL-6 fold-change | 1.39 Fold change in gene expression |
| Active Drug Tolerability | Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression | PBMC IL-8 fold-change | 1.79 Fold change in gene expression |
| Active Drug Tolerability | Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression | PBMC Matrix Metalloproteinase 1 (MMP1)fold-change | 1.21 Fold change in gene expression |
Comparison: PBMC IL-6 fold-changep-value: 0.68495% CI: [0.566, 2.337]t-test, 2 sided
p-value: 0.66395% CI: [0.331, 2.08]t-test, 2 sided
p-value: 0.595% CI: [0.691, 2.08]t-test, 2 sided
Secondary
Changes in Cytokine Levels in the Plasma
Target engagement will be assessed by mean change in plasma cytokine concentration between weeks 4 and 16 in ALS subjects receiving placebo or active drug.
Time frame: 16 weeks
Population: Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Placebo Tolerability | Changes in Cytokine Levels in the Plasma | CRP (ug/mL) | 1.051 Fold change in concentration |
| Placebo Tolerability | Changes in Cytokine Levels in the Plasma | IL-1beta (pg/mL) | 0.969 Fold change in concentration |
| Placebo Tolerability | Changes in Cytokine Levels in the Plasma | IL-6 (pg/mL) | 0.897 Fold change in concentration |
| Placebo Tolerability | Changes in Cytokine Levels in the Plasma | IL-8 (pg/mL) | 1.241 Fold change in concentration |
| Placebo Tolerability | Changes in Cytokine Levels in the Plasma | IL-17 (pg/mL) | 0.962 Fold change in concentration |
| Placebo Tolerability | Changes in Cytokine Levels in the Plasma | Tumor necrosis factor (TNF)-alpha (pg/mL) | 1.180 Fold change in concentration |
| Active Drug Tolerability | Changes in Cytokine Levels in the Plasma | IL-17 (pg/mL) | 1.342 Fold change in concentration |
| Active Drug Tolerability | Changes in Cytokine Levels in the Plasma | CRP (ug/mL) | 0.049 Fold change in concentration |
| Active Drug Tolerability | Changes in Cytokine Levels in the Plasma | IL-8 (pg/mL) | 1.569 Fold change in concentration |
| Active Drug Tolerability | Changes in Cytokine Levels in the Plasma | IL-1beta (pg/mL) | 1.266 Fold change in concentration |
| Active Drug Tolerability | Changes in Cytokine Levels in the Plasma | Tumor necrosis factor (TNF)-alpha (pg/mL) | 1.054 Fold change in concentration |
| Active Drug Tolerability | Changes in Cytokine Levels in the Plasma | IL-6 (pg/mL) | 17.974 Fold change in concentration |
p-value: <0.00195% CI: [0.01, 0.217]Mixed Models Analysis
p-value: 0.24795% CI: [0.828, 2.059]Mixed Models Analysis
p-value: <0.00195% CI: [11.143, 34.446]Mixed Models Analysis
p-value: 0.18595% CI: [0.892, 1.791]Mixed Models Analysis
p-value: 0.42795% CI: [0.608, 3.206]Mixed Models Analysis
p-value: 0.28595% CI: [0.725, 1.1]Mixed Models Analysis
Secondary
Peripheral Benzodiazepine Receptor 28 (PBR28) Positron Emission Tomography (PET)
Measure the effects of tocilizumab on reducing glial activation measured by PBR28 PET in a subset of trial participants.
Time frame: 8 weeks
Population: Only 2 patients met inclusion criteria for the PET portion of the study and thus, the data could not be statistically analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo Tolerability | Peripheral Benzodiazepine Receptor 28 (PBR28) Positron Emission Tomography (PET) | Week 8 | 1.361542 Standardized Uptake Variable Ratio(SUVR) |
| Placebo Tolerability | Peripheral Benzodiazepine Receptor 28 (PBR28) Positron Emission Tomography (PET) | Baseline | 1.225282 Standardized Uptake Variable Ratio(SUVR) |
| Active Drug Tolerability | Peripheral Benzodiazepine Receptor 28 (PBR28) Positron Emission Tomography (PET) | Week 8 | 1.056888 Standardized Uptake Variable Ratio(SUVR) |
| Active Drug Tolerability | Peripheral Benzodiazepine Receptor 28 (PBR28) Positron Emission Tomography (PET) | Baseline | 1.059685 Standardized Uptake Variable Ratio(SUVR) |
Secondary
Rate of Decline ALS Functional Rating Scale Revised (ALSFRS-R)
Efficacy will be assessed by the mean change in ALSFRS-R total score.The ALSFRS-R scale measures the functional capabilities of an ALS patient in multiple domains such as swallowing, speech, fine motor, and breathing functions. It ranges from a maximum score of 48 for normal functioning to 0 for death or dependance on mechanical ventilation and declines by approximately 1 point per month on average for an ALS patient.
Time frame: 16 weeks
Population: Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Tolerability | Rate of Decline ALS Functional Rating Scale Revised (ALSFRS-R) | -0.583 units on a scale | Standard Error 0.313 |
| Active Drug Tolerability | Rate of Decline ALS Functional Rating Scale Revised (ALSFRS-R) | -0.591 units on a scale | Standard Error 0.211 |
p-value: 0.98395% CI: [-0.761, 0.745]Mixed Models Analysis
Secondary
Rate of Decline Handheld Dynamometry (HHD)
Efficacy will be assessed by the change in the rate of change of HHD upper and lower extremity mega-scores. HHD utilizes an electronic pressure sensor to measure strength of individual muscles in kilograms. To calculate megascores, the mean and standard deviation of each muscle or muscle group, without regard to laterality, will be calculated from the baseline assessment of all participants. Strength estimates of each bilateral muscle or muscle group will be converted to Z scores by subtracting the relevant mean and dividing by the relevant standard deviation. Z scores for all upper extremity measurements (shoulder flexion, elbow flexion, elbow extension, wrist extension, and first dorsal interosseous contraction) and all lower extremity measurements (hip flexion, knee flexion, knee extension, and ankle dorsiflexion) will be averaged to yield upper and lower extremity megascores. Larger values indicate greater strength.
Time frame: 16 weeks
Population: Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Tolerability | Rate of Decline Handheld Dynamometry (HHD) | HHD Upper extremity mega-score | -0.028 Z-score | Standard Error 0.035 |
| Placebo Tolerability | Rate of Decline Handheld Dynamometry (HHD) | HHD Lower extremity mega-score | -0.018 Z-score | Standard Error 0.039 |
| Active Drug Tolerability | Rate of Decline Handheld Dynamometry (HHD) | HHD Upper extremity mega-score | -0.070 Z-score | Standard Error 0.024 |
| Active Drug Tolerability | Rate of Decline Handheld Dynamometry (HHD) | HHD Lower extremity mega-score | -0.032 Z-score | Standard Error 0.026 |
Secondary
Rate of Decline in Slow Vital Capacity (SVC)
Efficacy will be assessed by the change in the rate of change of SVC as measured by change in percent predicted per month. The SVC is a measure of lung capacity that is reported as the percent of the predicted value expected based on gender and height. In ALS patients, this measure declines over time as a result of progressive respiratory muscle weakness.
Time frame: 16 weeks
Population: Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Tolerability | Rate of Decline in Slow Vital Capacity (SVC) | -0.765 Percentage points change per month | Standard Error 0.829 |
| Active Drug Tolerability | Rate of Decline in Slow Vital Capacity (SVC) | -0.666 Percentage points change per month | Standard Error 0.56 |
p-value: 0.92295% CI: [-1.902, 2.099]Mixed Models Analysis